Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

FORMA THERAPEUTICS HOLDINGS, INC.

(FMTX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Forma Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for patients with rare hematologic diseases and cancers. Its pipeline consists of seven product candidates, two of which it is pursuing as core product candidates for development: FT-4202 for the treatment of sickle cell disease (SCD) and other hemoglobinopathies, and FT-7051 for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Its other product candidate includes FT-2102 (Olutasidenib), FT-8225, FT-4101, CC-95775 and BI-1701963. FT-4202 is an oral, once-daily, potentially disease-modifying therapy. FT-4202 is a potent activator of pyruvate kinase-R (PKR), designed to improve RBC metabolism, function and survival, and potentially resulting in both increased hemoglobin levels and reduced VOCs. FT-7051, is a potent and selective inhibitor of CREB-binding protein/E1A binding protein p300 (CBP/p300).

Number of employees : 107 people.
Sales per Business
20192020Delta
Biopharmaceutical100.56100%---
USD in Million
Sales per region
20192020Delta
United States100.56100%---
USD in Million
Managers
Name Title Age Since
Frank D. Lee President, Chief Executive Officer & Director 52 2019
Todd E. Shegog Chief Financial Officer & Senior Vice President 55 2019
David N. Cook, Dr. Chief Scientific Officer & Senior Vice President 62 2020
Patrick Kelly, Dr. Chief Medical Officer & Senior Vice President 56 2019
John E. Bishop, Dr. Chief Technology Officer 58 2021
Peter Wirth Chairman 69 2012
Timothy P. Clackson, Dr. Independent Non-Executive Director 54 2018
Marsha H. Fanucci Independent Non-Executive Director 66 2014
Peter Kolchinsky, Dr. Independent Non-Executive Director 43 2019
Wayne A. I. Frederick, Dr. Independent Director 48 2020
Members of the board
Name Title Age Since
Peter Wirth Chairman 69 2012
Frank D. Lee President, Chief Executive Officer & Director 52 2019
Timothy P. Clackson, Dr. Independent Non-Executive Director 54 2018
Marsha H. Fanucci Independent Non-Executive Director 66 2014
Peter Kolchinsky, Dr. Independent Non-Executive Director 43 2019
Wayne A. I. Frederick, Dr. Independent Director 48 2020
Thomas G. Wiggans Independent Director 68 2020
Selwyn M. Vickers, Dr. Independent Director - 2021
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 47,410,624 43,707,749 92.2% 37,966 0.1% 92.2%
Shareholders
NameEquities%
RA Capital Management LP 9,011,651 19.0%
Fidelity Management & Research Co. LLC 4,803,231 10.1%
Cormorant Asset Management LP 4,720,000 9.96%
Novartis Venture Funds 2,991,705 6.32%
Lilly Ventures Management Co. LLC 2,404,069 5.07%
The Vanguard Group, Inc. 2,123,371 4.48%
Baker Bros. Advisors LP 2,024,876 4.27%
SSgA Funds Management, Inc. 1,871,595 3.95%
EDB Investments Pte Ltd. 1,574,366 3.32%
Samsara Biocapital LLC 1,565,529 3.30%
Company contact information
Forma Therapeutics Holdings, Inc.
500 Arsenal Street
Suite 100
Watertown, MA 02472

Phone : +1.617.679.1970
Web : http://www.formatherapeutics.com
Sector Other Biotechnology & Medical Research
1st jan.Capi. (M$)
FORMA THERAPEUTICS HOLDINGS, INC.-34.41%1 084
MODERNA, INC.238.47%141 980
LONZA GROUP AG23.98%57 809
IQVIA HOLDINGS INC.38.25%47 462
CELLTRION, INC.-29.39%30 059
SEAGEN INC.-12.42%27 907
CUREVAC N.V.-39.24%21 497
ALNYLAM PHARMACEUTICALS, INC.37.68%21 034
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.62.86%20 449
PHARMARON BEIJING CO., LTD.64.43%20 226
ICON PUBLIC LIMITED COMPANY24.77%19 385
BIO-TECHNE CORPORATION51.86%18 755
HANGZHOU TIGERMED CONSULTING CO., LTD-2.48%18 276
INCYTE CORPORATION-11.07%17 011
PPD, INC.34.78%16 203
NOVAVAX, INC.60.82%13 285
QIAGEN N.V.-0.11%12 050
PRA HEALTH SCIENCES, INC.0.00%10 965
INTELLIA THERAPEUTICS, INC.160.75%10 305
BACHEM HOLDING AG51.71%9 267
SYNEOS HEALTH, INC.31.62%9 265